These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32486887)

  • 1. Peripheral Expression of
    Afzal M; Ali A; Sheikh N; Rafique S; Idrees M
    J Interferon Cytokine Res; 2020 Jun; 40(6):301-309. PubMed ID: 32486887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
    Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
    Rivero-Juarez A; Brieva T; Frias M; Rivero A
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
    BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
    Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
    J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
    Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
    Arab J Gastroenterol; 2024 May; 25(2):118-124. PubMed ID: 38378359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    Wahid B; Shami K; Joiya SA; Özuyar SEG; Idrees M
    J Med Virol; 2020 Dec; 92(12):3868-3870. PubMed ID: 32419178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.
    Said EM; Abdulaziz BA; El Kassas M; El Attar IH; Emadeldeen M; Abd-Elsalam SM
    Arch Virol; 2020 Jul; 165(7):1633-1639. PubMed ID: 32356185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Cheng PN; Chiu YC; Chien SC; Chiu HC
    J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
    Meissner EG; Decalf J; Casrouge A; Masur H; Kottilil S; Albert ML; Duffy D
    PLoS One; 2015; 10(7):e0133236. PubMed ID: 26181438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
    van der Ree MH; Stelma F; Willemse SB; Brown A; Swadling L; van der Valk M; Sinnige MJ; van Nuenen AC; de Vree JML; Klenerman P; Barnes E; Kootstra NA; Reesink HW
    Antiviral Res; 2017 Oct; 146():139-145. PubMed ID: 28844749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
    Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.